Rifaximin Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as SALIX PHARMS. It is marketed under 1 brand name, including XIFAXAN. Available in 1 different strength, such as 550MG, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"2487","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"444fde98745f4d9ba4dc","publication_number":"US7915275B2","cleaned_patent_number":"7915275","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-02-23","publication_date":"2011-03-29","legal_status":"Granted"} US7915275B2 29 Mar, 2011 Granted 23 Feb, 2025
{"application_id":"2486","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"444fde98745f4d9ba4dc","publication_number":"US7906542B2","cleaned_patent_number":"7906542","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-06-01","publication_date":"2011-03-15","legal_status":"Patented case"} US7906542B2 Molecular Formulation 15 Mar, 2011 Patented case 01 Jun, 2025
{"application_id":"2495","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"43e899bc41e34dff9cd0","publication_number":"US8518949B2","cleaned_patent_number":"8518949","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-02-27","publication_date":"2013-08-27","legal_status":"Granted"} US8518949B2 Formulation 27 Aug, 2013 Granted 27 Feb, 2026
{"application_id":"2503","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"43e899bc41e34dff9cd0","publication_number":"US9271968B2","cleaned_patent_number":"9271968","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-02-27","publication_date":"2016-03-01","legal_status":"Granted"} US9271968B2 Formulation 01 Mar, 2016 Granted 27 Feb, 2026
{"application_id":"103245","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"43e899bc41e34dff9cd0","publication_number":"US10703763B2","cleaned_patent_number":"10703763","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-02-27","publication_date":"2020-07-07","legal_status":"Granted"} US10703763B2 07 Jul, 2020 Granted 27 Feb, 2026
{"application_id":"2498","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"43e899bc41e34dff9cd0","publication_number":"US8741904B2","cleaned_patent_number":"8741904","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-02-27","publication_date":"2014-06-03","legal_status":"Granted"} US8741904B2 Molecular 03 Jun, 2014 Granted 27 Feb, 2026
{"application_id":"2493","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"43e899bc41e34dff9cd0","publication_number":"US8193196B2","cleaned_patent_number":"8193196","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-09-02","publication_date":"2012-06-05","legal_status":"Granted"} US8193196B2 Molecular Formulation 05 Jun, 2012 Granted 02 Sep, 2027
{"application_id":"110145","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"f7bb314f7e364f779501","publication_number":"US11564912B2","cleaned_patent_number":"11564912","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-02-26","publication_date":"2023-01-31","legal_status":"Granted"} US11564912B2 31 Jan, 2023 Granted 26 Feb, 2029
{"application_id":"37228","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"f7bb314f7e364f779501","publication_number":"US10456384B2","cleaned_patent_number":"10456384","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-02-26","publication_date":"2019-10-29","legal_status":"Granted"} US10456384B2 29 Oct, 2019 Granted 26 Feb, 2029
{"application_id":"18424","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"f7bb314f7e364f779501","publication_number":"US10765667B2","cleaned_patent_number":"10765667","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-02-26","publication_date":"2020-09-08","legal_status":"Granted"} US10765667B2 08 Sep, 2020 Granted 26 Feb, 2029
{"application_id":"32569","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"f7bb314f7e364f779501","publication_number":"US11779571B2","cleaned_patent_number":"11779571","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-02-26","publication_date":"2023-10-10","legal_status":"Granted"} US11779571B2 10 Oct, 2023 Granted 26 Feb, 2029
{"application_id":"18437","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"f7bb314f7e364f779501","publication_number":"US8309569B2","cleaned_patent_number":"8309569","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-18","publication_date":"2012-11-13","legal_status":"Granted"} US8309569B2 13 Nov, 2012 Granted 18 Jul, 2029
{"application_id":"121516","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US9629828B2","cleaned_patent_number":"9629828","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2017-04-25","legal_status":"Patented case"} US9629828B2 25 Apr, 2017 Patented case 24 Jul, 2029
{"application_id":"103222","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US10335397B2","cleaned_patent_number":"10335397","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2019-07-02","legal_status":"Granted"} US10335397B2 02 Jul, 2019 Granted 24 Jul, 2029
{"application_id":"103223","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US10709694B2","cleaned_patent_number":"10709694","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2020-07-14","legal_status":"Granted"} US10709694B2 14 Jul, 2020 Granted 24 Jul, 2029
{"application_id":"2489","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US7928115B2","cleaned_patent_number":"7928115","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2011-04-19","legal_status":"Granted"} US7928115B2 19 Apr, 2011 Granted 24 Jul, 2029
{"application_id":"2499","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US8829017B2","cleaned_patent_number":"8829017","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2014-09-09","legal_status":"Patented case"} US8829017B2 09 Sep, 2014 Patented case 24 Jul, 2029
{"application_id":"121512","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US8946252B2","cleaned_patent_number":"8946252","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2015-02-03","legal_status":"Granted"} US8946252B2 03 Feb, 2015 Granted 24 Jul, 2029
{"application_id":"2504","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US9421195B2","cleaned_patent_number":"9421195","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2016-08-23","legal_status":"Granted"} US9421195B2 23 Aug, 2016 Granted 24 Jul, 2029
{"application_id":"103221","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US10314828B2","cleaned_patent_number":"10314828","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-07-24","publication_date":"2019-06-11","legal_status":"Granted"} US10314828B2 11 Jun, 2019 Granted 24 Jul, 2029
{"application_id":"121514","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US8969398B2","cleaned_patent_number":"8969398","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-02","publication_date":"2015-03-03","legal_status":"Granted"} US8969398B2 03 Mar, 2015 Granted 02 Oct, 2029
{"application_id":"2497","ingredient":"RIFAXIMIN","trade_name":"XIFAXAN","family_id":"2408637612404cc79f37","publication_number":"US8642573B2","cleaned_patent_number":"8642573","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-02","publication_date":"2014-02-04","legal_status":"Patented case"} US8642573B2 04 Feb, 2014 Patented case 02 Oct, 2029

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Rifaximin

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.